Literature DB >> 9682349

A benefit-cost analysis of two-dose measles immunization in Canada.

L Pelletier1, P Chung, P Duclos, P Manga, J Scott.   

Abstract

In 1992, because of the limitations of the one-dose measles immunization program, the National Advisory Committee on Immunization (NACI) recommended a two-dose measles immunization program to eliminate measles. More recently, NACI recommended also a special catch-up program to prevent predicted measles outbreaks and to achieve an earlier elimination of measles. The objective of this study was to complete a benefit-cost analysis of a two-dose immunization program with and without a mass catch-up compaign compared with the current one-dose program. The resulting benefit: cost ratios vary between 2.61:1 and 4.31:1 depending on the strategy used and the age of the children targeted. Given the parameters established for this analysis, the benefits of a second-dose vaccination program against measles far outweight the costs of such a program under all scenarios.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682349     DOI: 10.1016/s0264-410x(97)00281-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta.

Authors:  S L Lee; P Etches; J L Robinson
Journal:  Paediatr Child Health       Date:  2001-10       Impact factor: 2.253

2.  Another look at the human papillomavirus vaccine experience in Canada.

Authors:  Catherine L Mah; Raisa B Deber; Astrid Guttmann; Allison McGeer; Murray Krahn
Journal:  Am J Public Health       Date:  2011-08-18       Impact factor: 9.308

3.  Economic burden and associated factors of measles patients in Zhejiang Province, China.

Authors:  Xuan Deng; Hanqing He; Yang Zhou; Shuyun Xie; Ya Fang; Yanbing Zeng; Rui Yan; Xuewen Tang; Jian Fu
Journal:  Hum Vaccin Immunother       Date:  2019-04-22       Impact factor: 3.452

4.  Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet.

Authors:  Robert J Ledogar; John Fleming; Neil Andersson
Journal:  BMC Int Health Hum Rights       Date:  2009-10-14

Review 5.  Health economics of rubella: a systematic review to assess the value of rubella vaccination.

Authors:  Joseph B Babigumira; Ian Morgan; Ann Levin
Journal:  BMC Public Health       Date:  2013-04-29       Impact factor: 3.295

6.  The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.

Authors:  Kenzo Takahashi; Yasushi Ohkusa; Jong-Young Kim
Journal:  BMC Health Serv Res       Date:  2011-10-07       Impact factor: 2.655

7.  Modelling the effect of a booster vaccination on disease epidemiology.

Authors:  M E Alexander; S M Moghadas; P Rohani; A R Summers
Journal:  J Math Biol       Date:  2005-11-10       Impact factor: 2.164

Review 8.  Measles vaccines: a review of adverse events.

Authors:  P Duclos; B J Ward
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.228

9.  Health burden and economic impact of measles-related hospitalizations in Italy in 2002-2003.

Authors:  Antonietta Filia; Antonio Brenna; Augusto Panà; Gianluca Maggio Cavallaro; Marco Massari; Marta L Ciofi degli Atti
Journal:  BMC Public Health       Date:  2007-07-24       Impact factor: 3.295

10.  The average cost of measles cases and adverse events following vaccination in industrialised countries.

Authors:  Hélène Carabin; W John Edmunds; Ulla Kou; Susan van den Hof; Van Hung Nguyen
Journal:  BMC Public Health       Date:  2002-09-19       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.